http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
-
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
-
Pfizer (PFE), BioNTech (BNTX) Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
-
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
-
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
-
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
-
Pfizer (PFE) Announces Agreement to Supply 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to US Govt
-
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
-
Pfizer Completes Acquisition of Trillium Therapeutics
-
Pfizer (PFE) Announces CFO Retirement
-
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
-
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
-
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
-
Pfizer (PFE) Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
-
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
-
Pfizer (PFE) Announces Licensing Agreement with Medicines Patent Pool (MPP) for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
-
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
-
Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Biohaven Pharma (BHVN) Announces Strategic Collaboration with Pfizer (PFE) for Commercialization of Rimegepant Outside the US
-
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
-
Pfizer's (PFE) COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
-
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
-
Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children Aged 5-11
-
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
-
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
-
Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
-
US Govt Purchases Additional 50M Doses of Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine
-
Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
-
FDA AdCom Votes in Favor of Emergency Use Authorization for Pfizer (PFE) and BioNTech's (BNTX) Covid-19 Vaccine in Children 5 to <12 Years
-
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
-
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
-
Pfizer (PFE) and BioNTech (BNTX) Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer (PFE) and BioNTech SE (BNTX) Report Phase 3 Data Confirming High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer (PFE) Announces Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20 in Adults
-
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults
-
Myovant Sciences (MYOV) and Pfizer (PFE) Report Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis
-
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
-
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
-
Pfizer (PFE) Announces Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
-
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
-
Data suggests mRNA booster dose generates stronger antibody response after J&J shot - Axios
-
Pfizer, BioNTech seek U.S. COVID-19 vaccine clearance for children 5-11
-
Voyager Therapeutics (VYGR) Announces License Option Agreement with Pfizer (PFE) for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
-
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
-
Pfizer (PFE) Announces Japan’s MHLW Approves CIBINQO for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
-
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
-
Pfizer (PFE) Announces Positive Top-line Results of Phase 3 Study Exploring Coadministration of Prevnar 20 With Seasonal Flu Vaccine in Older Adults Released

